The Egyptian Drug Authority (EDA) published its third version of the Good Pharmacovigilance Practice (GVP) guideline in 2026, representing a significant evolution in Egypt’s pharmacovigilance regulatory framework. This comprehensive document, legalized by EDA chairman decree 382/2023, establishes the standards for pharmacovigilance systems and activities within Egypt. The guideline is substantially based on the European Medicines Agency’s GVP modules but incorporates national requirements specific to the Egyptian healthcare context.
The legal framework underpinning this guideline includes ministerial decrees 368/2012, 151/2019, 2/2010, 777/2020, 184/2023, and 382/2023. This regulatory architecture positions the EDA as the central authority coordinating pharmacovigilance activities while imposing specific obligations on marketing authorization holders (MAHs).
Part I: The Pharmacovigilance System and Quality Management
Definition and Scope
The guideline defines a pharmacovigilance system as “a system used by the marketing authorization holder and by EDA to fulfill the pharmacovigilance tasks and responsibilities… designed to monitor the safety of authorized pharmaceutical products and detect any change to their risk-benefit balance”. This definition establishes the dual responsibility shared between MAHs and the regulatory authority.
Quality System Requirements
The quality system must cover organizational structure, responsibilities, procedures, processes, resources, resource management, compliance management, and record management. The quality cycle is built on four interconnected activities: quality planning, quality adherence, quality control and assurance, and quality improvements.
Overall Quality Objectives
The guideline establishes four primary quality objectives for pharmacovigilance systems:
- Complying with legal requirements for pharmacovigilance tasks
- Preventing harm from adverse reactions arising from product use or occupational exposure
- Promoting safe and effective use through timely safety information dissemination
- Contributing to the protection of patients and public health
The Qualified Person for Pharmacovigilance (QPPV)
A critical element of the pharmacovigilance system is the QPPV, who must be “permanently and continuously” available. The QPPV must hold a minimum of a bachelor’s degree in pharmacy or medicine with basic training in epidemiology and biostatistics. For multinational companies, a Local Safety Responsible (LSR) must be nominated in Egypt.
The QPPV’s responsibilities extend to:
- Having overview of product safety profiles and emerging safety concerns
- Awareness of risk minimization measures and risk management plans
- Ensuring conduct of pharmacovigilance and submission of all pharmacovigilance-related documents
- Acting as the single pharmacovigilance contact point for EDA on a 24-hour basis
Critical Pharmacovigilance Processes
The guideline identifies specific processes as “critical”:
- Continuous safety profile monitoring and benefit-risk evaluation
- ICSR collection, processing, management, and timely electronic transmission
- Signal management
- Periodic safety update report preparation and submission
- Communication about safety concerns
- Keeping product information up-to-date with current scientific knowledge
Business Continuity and Crisis Management
MAHs must establish business continuity plans for events that could severely impact pharmacovigilance structures and processes. Crisis prevention focuses on proactive risk management, maintaining a high state of alert for early signals, and reputation management through open communication.
Part II: Pharmacovigilance System Master File (PSMF)
Purpose and Requirements
The PSMF is a legal requirement providing “a detailed description of the pharmacovigilance system used by the marketing authorization holder with respect to one or more authorized pharmaceutical products”. For multinational MAHs, two documents are required: the global PSMF and a National Pharmacovigilance Sub-System File (National PSSF) describing pharmacovigilance activities in Egypt.
Content Requirements
The PSMF must contain comprehensive information including:
- QPPV/LSR details with qualification evidence
- Organizational structure of the MAH
- Sources of safety data
- Computerized systems and databases
- Pharmacovigilance processes
- Pharmacovigilance system performance metrics
- Quality system documentation
- Product lists and contractual agreements
Performance Indicators
The guideline establishes that “the accepted target is not less than 90%” for pharmacovigilance system performance, with expectation of continuous improvement. Performance indicators must include timeliness of 15-day and 90-day reporting, PSUR submission timelines, and adherence to risk management plan commitments.
Accessibility and Submission
The PSMF must be “permanently available to the QPPV” and submitted to EDA within 14 days of request. Full PSMF submission is required in specific situations including new MAHs without previous Egyptian authorization, major changes to the pharmacovigilance system, mergers and acquisitions, and where previous non-compliance has been identified.
Part III: Pharmacovigilance Inspections
Inspection Objectives and Types
Pharmacovigilance inspections aim to:
- Determine that MAHs have personnel, systems, and facilities meeting pharmacovigilance obligations
- Identify and address non-compliance that may pose risks to public health
- Provide basis for enforcement action when necessary
Inspections are categorized as:
- System vs. product-related inspections: System inspections review overall procedures, while product-related inspections focus on specific product issues
- Routine vs. “for cause” inspections: Routine inspections follow risk-based scheduling; “for cause” inspections are triggered by specific concerns
- Pre-authorization vs. post-authorization: Pre-authorization inspections examine proposed systems before marketing authorization
- Announced vs. unannounced: Most are announced, but unannounced inspections may occur when announcement would compromise objectives
Risk-Based Inspection Planning
The guideline mandates a risk-based approach considering factors including:
- Compliance history from previous inspections
- Product characteristics (additional monitoring status, safety profile)
- MAH characteristics (number of products, resources, organizational changes)
- Pharmacovigilance system characteristics (subcontracted activities, database changes)
Inspection Frequency
As a general approach, “it is recommended to routinely inspect MAH at least once every 4 years”. Re-inspections may be conducted earlier when significant non-compliance has been identified.
Part IV: Pharmacovigilance Audits
Definition and Objectives
A pharmacovigilance audit is defined as “a systematic, disciplined, independent and documented process for obtaining evidence and evaluating the evidence objectively to determine the extent to which the audit criteria are fulfilled”. Audits verify the appropriateness and effectiveness of pharmacovigilance system implementation and operation.
Risk-Based Approach
The guideline establishes a three-level risk-based approach:
- Strategic level: Long-term audit strategy (2-5 years) endorsed by upper management
- Tactical level: Annual audit programme with defined scope and objectives
- Operational level: Individual audit plans with risk-based sampling and testing
Findings Grading
Audit findings are graded according to risk level:
- Critical: Fundamental weakness adversely affecting the whole pharmacovigilance system and/or patient safety
- Major: Significant weakness potentially affecting patient safety
- Minor: Weakness not expected to adversely affect the system or patient safety
Independence and Objectivity
“Pharmacovigilance audit activities shall be independent”. Auditors must maintain an unbiased attitude and not subordinate their judgment to others. The QPPV must receive audit reports and be notified of findings relevant to the pharmacovigilance system.
Part V: Risk Management Systems
Core Concepts
The guideline defines key risk management terminology:
- Identified risk: An untoward occurrence with adequate evidence of association
- Potential risk: An occurrence with some basis for suspicion but unconfirmed association
- Missing information: Gaps in knowledge about safety that could be clinically significant
- Important risk: A risk that could impact the risk-benefit balance or have public health implications
Risk Management Plan (RMP) Structure
The RMP consists of seven parts:
- Part I: Product(s) overview
- Part II: Safety specification (8 modules covering epidemiology, non-clinical data, clinical trial exposure, populations not studied, post-authorization experience, identified and potential risks)
- Part III: Pharmacovigilance plan
- Part IV: Plans for post-authorization efficacy studies
- Part V: Risk minimization measures
- Part VI: Summary of the risk management plan
- Part VII: Annexes
Routine vs. Additional Risk Minimization
Routine risk minimization applies to all products and includes:
- Summary of product characteristics (SmPC)
- Labelling and package leaflet
- Pack size
- Legal status
Additional risk minimization measures are introduced when routine measures are insufficient and may include:
- Educational programs
- Controlled access programs
- Direct healthcare professional communication (DHPC)
- Pregnancy prevention programs
Egyptian Display of RMP
For MAHs with EU/global RMPs, an “Egyptian Display of the RMP” must be submitted alongside the global document. This display highlights which activities will be implemented in Egypt and provides justification for any differences from the global plan.
Part VI: Individual Case Safety Report (ICSR) Management
Definitions and Terminology
The guideline establishes comprehensive definitions:
- Adverse Event (AE) : Any untoward medical occurrence, not necessarily causal
- Adverse Drug Reaction (ADR) : A response that is noxious and unintended, with at least a reasonable possibility of causal relationship
- Serious AE/ADR: Results in death, is life-threatening, requires hospitalization, causes persistent disability, or is a congenital anomaly
- Unexpected AE/ADR: Not included in the product labelling
ICSR Validation
ICSRs require four minimum criteria for submission:
- One or more identifiable reporter
- One single identifiable patient
- One or more suspected substance/pharmaceutical product
- One or more suspected adverse reactions
Submission Timelines
The guideline establishes specific timelines:
- Serious ICSRs: Within 15 calendar days from receipt
- Non-serious ICSRs: Within 90 calendar days from receipt
- Emergency Use Authorization (EUA) products: Serious cases within 24 hours, non-serious within 7 days
Follow-up Requirements
Follow-up is required “to obtain supplementary detailed information significant for the scientific evaluation of the cases”. Priority levels for follow-up are established:
- Priority 1: Serious unexpected reports and action-requiring events
- Priority 2: Serious expected reports and non-serious action-requiring events
- Priority 3: Non-serious reports
Part VII: Periodic Benefit-Risk Evaluation Report (PBRER)
Purpose and Scope
The PBRER aims to present “a comprehensive, concise and critical analysis of the risk-benefit balance of the pharmaceutical product taking into account new or emerging information”. The guideline adopts the ICH E2C(R2) format and content standards.
Submission Timelines
PBRERs must be submitted:
- Within 70 calendar days of the data lock point for intervals up to 12 months
- Within 90 calendar days for intervals exceeding 12 months
EU Reference Dates (EURD)
Egypt has adopted the EU reference dates list for PBRER submission harmonization. For active substances not on the EURD list, MAHs check the EDA PBRER supplementary list or submit a proposal request to define frequency.
PBRER Structure
The PBRER includes 20 sections covering:
- Worldwide marketing authorization status
- Actions taken for safety reasons
- Estimated exposure and use patterns
- Summary tabulations of safety data
- Signal and risk evaluation
- Benefit evaluation
- Integrated benefit-risk analysis
- Conclusions and actions
Part VIII: Signal Management
Definition of Signal
According to the WHO definition adopted by the guideline, a signal is “information arising from one or multiple sources… which suggests a new potentially causal association, or a new aspect of a known association… that is judged to be of sufficient likelihood to justify verificatory action”.
Signal Management Process
The signal management process includes:
- Signal detection: Looking for potential safety signals from any source
- Signal prioritization: Identifying signals with potential public health impact
- Signal validation: Evaluating data to verify sufficient evidence for further analysis
- Signal assessment: Comprehensive evaluation to determine if new risks exist
- Recommendations for action: Communicating validated signals to stakeholders
Signal Status Categories
Signals are tracked with specific statuses:
- Non-validated – known: Already labelled or previously alerted
- Non-validated – other: Refuted due to confounders or other reasons
- Validated – for assessment: Justifies further analysis
- Assessed – for action: Causal association established
- Assessed – no action: Refuted or indeterminate
Standalone Signal Notification
MAHs must submit standalone signal notifications within 45 calendar days of validation. For non-referenced biosimilars and innovative products with domestic cases, a Signal Evaluation Report (SER) must be provided.
Part IX: Post-Authorization Safety Studies (PASS)
Definition and Scope
PASS is defined as “any study relating to an authorized pharmaceutical product conducted with the aim of identifying, characterizing or quantifying a safety hazard or a lack of efficacy, confirming the safety profile of the pharmaceutical product, or measuring the efficacy of a product in post-marketing setting”.
Study Types
The guideline describes multiple study methodologies:
- Active surveillance: Continuous organized process to ascertain adverse events
- Intensive monitoring: Record collection in designated areas with trained monitors
- Prescription Event Monitoring (PEM) : Follow-up questionnaires to prescribing physicians
- Registries: Organized systems collecting uniform data on defined populations
- Observational studies: Cross-sectional, cohort, case-control, and case-only designs
Protocol Requirements
All PASS must have a written study protocol before commencement. The protocol must include: title, MAH details, responsible parties, abstract, amendments, milestones, rationale, research objectives, methods, data sources, study size, data management, quality control, limitations, and protection of human subjects.
Final Study Report
The final study report must be submitted within 12 months of the end of data collection. It must include: title, abstract, MAH details, investigators, milestones, rationale, objectives, amendments, research methods, results, and discussion.
Part X: Safety Communication
Objectives and Principles
Safety communication aims to:
- Provide timely, evidence-based information on safe and effective medicine use
- Facilitate changes to healthcare practices
- Change attitudes, decisions, and behaviors
- Support risk minimization behavior
- Facilitate informed decisions on rational medicine use
Direct Healthcare Professional Communication (DHPC)
DHPCs are “communication intervention[s] by which important safety information is delivered directly to individual healthcare professionals”. DHPCs require EDA approval before dissemination and must include:
- Important new information impacting risk-benefit balance
- Clear explanation of the reason for communication
- Recommendations for healthcare professionals and patients
- Statement on agreement between MAH and EDA
Emerging Safety Issues (ESI)
ESIs are defined as “safety concern[s]… considered by a marketing authorization holder or identified by EDA to require urgent attention because of: (a) the potential major impact on the risk-benefit balance of the product; and/or (b) a significant threat to patients’ or public health; and (c) the potential need for prompt regulatory action and/or communication”.
ESIs must be notified “immediately (no later than 5 working days)” after publication or implementation in other regulatory authorities.
Part XI: Additional Monitoring
Purpose and Scope
Additional monitoring aims to strengthen safety monitoring for products where the safety profile may not be fully characterized. Products subject to additional monitoring are identified by an inverted equilateral black triangle symbol.
Mandatory Inclusion Criteria
Products that must be included in additional monitoring:
- Products containing a new active substance not previously in any innovative product
- Any biological product authorized after 1 July 2015
- Products where a PASS was requested at authorization
- Products with specific obligations on recording adverse reactions
- Products granted conditional marketing authorization
- Products authorized under exceptional circumstances
Black Triangle Statement
The SmPC must include: “This pharmaceutical product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions”.
Part XII: Risk Minimization Measures
Selection Principles
Risk minimization measures aim to “optimize the safe and effective use of a pharmaceutical product throughout its life cycle”. Additional risk minimization measures should focus on “the most important, preventable risks and the burden of imposing additional risk minimization shall be balanced with the benefit for patients”.
Educational Programmes
Educational materials must:
- Focus on actionable goals
- Provide clear, concise messages
- Be fully aligned with approved product information
- Be non-promotional
- Be completely separated from promotional activities
Effectiveness Evaluation
Two categories of indicators must be considered:
- Process indicators: Measure implementation extent (distribution, receipt, knowledge assessment)
- Outcome indicators: Measure level of risk control achieved (frequency/severity of adverse reactions)
Periodic Review
Effectiveness evaluation should be conducted at appropriate times, particularly:
- After initial implementation (within 12-18 months)
- In time for marketing authorization renewal
- When new information becomes available
Part XIII: Biological Products
Specific Challenges
Biological products present unique pharmacovigilance challenges due to:
- Complex molecular structure with inherent variability
- Manufacturing process as a determinant of quality, safety, and efficacy
- Greater potential risk of immunogenicity
- Need for continuous product and batch traceability
Immunogenicity Management
“Immunogenicity shall be reflected in the risk management plan (RMP)”. The RMP must include relevant strategies for evaluating immunogenicity and associated clinical consequences in the post-authorization setting.
Traceability Requirements
“A key requirement for pharmacovigilance of biologicals is the need to ensure continuous product and batch traceability in clinical use”. This is “especially important for biologicals compared to chemically-synthesized medicines due to a greater inherent variability in product characteristics”.
Biosimilar Requirements
For biosimilars, “any specific safety monitoring imposed on the reference product shall be adequately addressed in the pharmacovigilance plan of the biosimilar”. Risk minimization activities for the reference product must, in principle, be included in the biosimilar’s RMP.
Key Differences Between Version 3 (2026) and Previous Versions
Based on the comprehensive history table included in the guideline, the major updates in Version 3 include:
Chapter 1 (Pharmacovigilance Systems)
- Added requirement for “effective internal and external official communication” in record management
- Clarified that QPPV/LSR staff can be in any department except quality to avoid conflict of interest
- Specified retention periods: patient documents lifelong, product documents 10 years post-authorization, company documents 5 years post-authorization
- Added weekly backup requirements for electronic systems
Chapter 6 (ICSR Management)
- Substantially expanded definitions including Adverse Event (AE), Adverse Drug Reaction (ADR), Unexpected AE/ADR, and Other Observations
- Added definitions for Digital Platform, Organised Data Collection System (ODCS), Patient Support Program (PSP), and Market Research Program (MRP)
- Updated seriousness criteria to align with ICH E2A Guideline
- Added detailed guidance on literature monitoring and handling of cases from digital platforms
- Introduced Market Research Programs (MRPs) within solicited reports
- Added clarification that submission timelines are based on calendar days
Chapter 7 (PBRER)
- Added reference to “EDA PBRER supplementary list” for active ingredients not on EURD list
- Removed previous exemptions for generic products, well-established use products, homeopathic products, and traditional herbal products
- Updated national appendix requirements for current product information
Chapter 8 (Signal Management)
- Updated definition of VigiBase
- Removed “refuted” from indeterminate signal definition
- Expanded Emerging Safety Issue (ESI) definition with new categories including:
- Safety issues from real-world evidence sources
- AI-based signal detection systems meeting ESI criteria
- Safety concerns from regulatory inspections (GMP, GVP, GCP)
Chapter 9 (PASS)
- Added “Case-only designs” as a subtype under observational studies
- Added comprehensive sections on Active Surveillance, Intensive Monitoring Schemes, Prescription Event Monitoring, and Registries
- Added detailed subsections on Cross-sectional Studies, Cohort Studies, Case-control Studies, and Case-only Designs
- Added “Interim Report” as a distinct study report category
- Modified publication timeline requirements for study results
Chapter 10 (Safety Communication)
- Modified ESI definition in subsection 10.3.2.1 and Annex I
- Added new ESI categories including quality defects with clinical consequences and safety concerns from inspections
Chapter 12 (Risk Minimization)
- Clarified MAH responsibility for distribution of approved RMMs and ensuring continued availability
- Added “Quality assurance mechanisms” subsection
- Added “Use of electronic features (e.g. QR codes)” to educational tools
- Added EDA follow-up requirements for RMM dissemination including follow-up calls/emails
- Added formal notification to MAHs on progress report outcomes
- Added “Redistribution of Additional risk minimization measures” subsection
- Added requirement for MAHs to submit Progress reports on Compliance follow-up Portal
References
- Added ICH Harmonised Guideline E2D(R1): “Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports”
Conclusion
The Egyptian Drug Authority’s GVP Guideline Version 3 (2026) represents a comprehensive and scientifically rigorous framework for pharmacovigilance in Egypt. Building on the foundation of European GVP modules while incorporating national requirements, the guideline establishes clear expectations for MAHs across all aspects of pharmacovigilance—from quality systems and PSMF maintenance through ICSR management, signal detection, risk management, and safety communication.
The substantial updates in Version 3 reflect the evolving international pharmacovigilance landscape, with particular emphasis on biological products, digital pharmacovigilance, risk minimization effectiveness evaluation, and emerging safety issues. The alignment with ICH guidelines and the adoption of EU reference dates for PBRER submission demonstrate Egypt’s commitment to international harmonization while maintaining the flexibility to address national public health priorities.
For MAHs operating in Egypt, compliance with this guideline is not merely a regulatory obligation but a fundamental component of patient safety and public health protection. The emphasis on quality systems, performance monitoring, and continuous improvement positions Egypt’s pharmacovigilance framework among the most robust in the region.
